A Meta-Analysis: Tandem Vs Single Autologous Hematopoietic Cell Transplantation Myeloma - JNCI 2009
NCT01023308: Phase 3 - Panobinostat or Placebo With Bortezomib & Dex in Relapsed Myeloma PANORAMA-1
NCT00747877: Phase 3: HDM and second HSCT or Low dose Dex in Myeloma RRMM - Myeloma X Relapse
NCT00722566: Phase 3: A Study of Subcutaneous and Intravenous VELCADE in Patients With RRMM
NCT00424047: Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma
NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
NCT00574288: Phase 1/2: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - GEN501 study
Incorporating bortezomib into upfront treatment for multiple myeloma: early results total therapy 3
NCT00098475: Phase 3: Lenalidomide and Dexamethasone With or Without Thalidomide in Multiple Myeloma
PMID 6546971: Effective treatment of advanced multiple myeloma refractory to alkylating agents
Single versus double autologous stem-cell transplantation for multiple myeloma
NCT00056160 : Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma
NCT00048230: Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With RRMM
Phase 2: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma - NEJM 1999
Results of autologous stem cell transplant in multiple myeloma patients with renal failure